According to the updated findings of this single-arm, multicenter study in 108 pretreated advanced CCA with FGFR2 fusion or rearrangement, infigratinib showed an overall response rate (ORR) of 23.1%, with a median duration of response of 5.0 months and median PFS of 7.3 months [65]. The gene discussed is FGFR2; the disease is cholangiocarcinoma.